^(99)Tc^m-MIBI在检测乳腺癌中的作用

The role of^(99)Tc^m -sestamibi in breast cancer diagnosis

99Tcm- MIBI(99Tcm-甲氧基异丁基异腈 )是第一个经 FDA (美国食品和药物管理局 )批准作为乳腺显像剂的放射性药物。一些前瞻性研究已经显示 ,99Tcm- MIBI检测乳腺癌的敏感性为 85 % ,特异性 89% ,阳性和阴性预测率分别是 89%和 84%。核素检测乳腺癌有其特殊的临床意义 ,特别是用于那些不能诊断和诊断有困难的乳腺疾病 ,评价高危人群 。

Tc m sestamibi was the first radiopharmaceutical to be approved by the FDA (Food and Drug Administration) for scintimammography. Some prospective studies have shown that the overall sensitivity of 99 Tc m sestamibi scintimammography in detection of breast cancer was 85%, the specificity was 89%, and the positive and negative predictive values were 89% and 84% respectively. Scintimammography plays a special role in various clinical indications such as nondiagnostic or diffcult mammography and evaluation of high risk patients,tumor response to chemotherapy,and axillary lymph node metastatic involvement.